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Abstract   
Background 
Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed in late adulthood; therefore, 
many patients suffer or have suffered from other diseases. Identifying disease-patterns 
associated with PDAC risk may enable a better characterization of high-risk patients.  
Methods    
Multimorbidity patterns (MPs) were assessed from 17 self-reported conditions using hierarchical 
clustering, principal component, and factor analyses in 1705 PDAC cases and 1084 controls 
from a European population. Their association with PDAC was evaluated using adjusted logistic 
regression models. Time since diagnosis of morbidities to PDAC diagnosis/recruitment was 
stratified into recent (<3 years) and long-term (>3 years). The MPs and PDAC genetic networks 
were explored with DisGeNET bioinformatics-tool which focuses on gene-diseases associations 
available in curated databases. 
Results 
Three MPs were observed: gastric (heartburn, acid regurgitation, H. pylori infection, and ulcer), 
metabolic syndrome (obesity, type-2 diabetes, hypercholesterolemia, and hypertension), and 
atopic (nasal allergies, skin allergies, and asthma). Strong associations with PDAC were 
observed for ≥2 recently diagnosed gastric conditions (odds ratio [OR], 6.13; 95%CI 3.01-12.5) 
and for ≥3 recently diagnosed metabolic syndrome conditions (OR, 1.61; 95%CI 1.11-2.35). 
Atopic conditions were negatively associated with PDAC (high adherence score OR for tertile 
III, 0.45; 95%CI 0.36 – 0.55). Combining type-2 diabetes with gastric MP resulted in higher 
PDAC risk for recent (OR, 7.89; 95%CI 3.9-16.1) and long-term diagnosed conditions (OR, 
1.86; 95%CI 1.29-2.67). A common genetic basis between MPs and PDAC was observed in the 
bioinformatics analysis.  
Conclusions  
Specific multimorbidities aggregate and associate with PDAC in a time-dependent manner. A 
better characterization of a high-risk population for PDAC may help in the early diagnosis of this 
cancer. The common genetic basis between MP and PDAC points to a mechanistic link 
between these conditions. 
 
Keywords 
Pancreatic cancer; Multimorbidity; Risk. 
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Key Message (400characters max (spaces included)= 397) 
We explored the co-occurrence of morbidities and their common effect on pancreatic cancer. 
We showed that some groups of morbidities cluster together. Given that multimorbidity is 
frequent in the adult population, evaluating the collective effect of patterns of conditions will 
allow a better characterization of risk for this malignancy potentially improving the management 
of affected patients.  
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is a dreadful disease usually diagnosed in late 
adulthood; hence, many patients suffer from other diseases [1,2]. PDAC patients present 
certain morbidities more often than non-PDAC patients, including chronic pancreatitis, type two 
diabetes mellitus (T2DM) or obesity [3–5]. Few studies focus in constellations of morbidities, 
and most explore associations between individual conditions and PDAC risk. In PDAC, 
multimorbidity has been mainly studied in the context of the metabolic syndrome (MetS), a 
cluster of conditions including abdominal obesity, hypertension, fasting hyperglycemia and 
serum hypertriglyceridemia, and low HDL cholesterol [6]. Having >3 MetS conditions has been 
associated with a 2-fold increased PDAC risk [7] yet, few studies have characterized in detail 
this relationship [8–12]. Additional multimorbidity patterns (MPs) affecting PDAC might exist, 
providing key information on disease mechanisms and contributing to the development of 
strategies to improve risk assessment. 
We explored the patterns of co-occurrence of 17 self-reported medical conditions and 
their association with PDAC in a European case-control population. Identifying MPs and 
evaluating their effect on PDAC risk provides clues on common (genetic and/or environmental) 
backgrounds and allow us to obtain a finer characterization of risk. The assessment of time 
since diagnosis of these conditions allowed us to evaluate whether the morbidities represent a 
risk factor or an early manifestation of the malignancy.  
 
Methods 
Study population 
The PanGenEU case-control study recruited PDAC patients >18 years old from Spain, United 
Kingdom, Germany, Ireland, Italy, and Sweden between 2009 and 2014 (Supplementary Annex 
S1, Table S2). Italy contributed with cases only. Controls were hospital-based, except in Ireland 
and Sweden where controls were population-based. Controls had no history of PDAC and 
principal diagnosis at admission was unrelated to known risk factors of PDAC (Supplementary 
Table S1). Response rate was  86.3% in cases and 77.8% in controls. IRB approval and written 
informed consent were obtained from all centers and participants. 
Health monitors performed in-person interviews; subjects answered “yes/no” to “Has 
your doctor ever told you that you had any of the following illnesses, health problems or 
procedures?” for 25 medical conditions (Supplementary TableS3). Obesity (Body mass index, 
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BMI >30 kg/m2) was calculated using reported usual adult height and weight two years before 
recruitment. Only conditions with prevalence >2% were considered. Subjects without 
information in the medical questions  were removed (n=268, 8.8%), leaving 1705 cases and 
1084 controls. Age, sex and smoking were not statistically different between included and 
excluded subjects (p-value >0.05).  
 
Statistical analysis   
Data was imputed using missForest R package (Supplementary Methods). Adjustment variables 
were selected using the 10% change of estimate method. Statistical significance was 
considered as p-value <0.05. Analyses were performed using R version 3.1.2. 
All combinations of two (comorbidity) and three morbidities (trimorbidity) within an 
individual were considered (Supplementary Methods). MPs were defined separately for cases 
and controls using hierarchical cluster analysis, principal component (PCA), and factor (FA) 
analyses (Supplementary Methods). Variables were created by combining presence/absence of 
conditions (0=none, 1=any one, 2=any two, 3=any three or more) for gastric (H. pylori, acid 
regurgitation, heartburn and ulcer), MetS (T2D, hypertension, obesity and 
hypercholesterolemia), and atopic (asthma, nasal and skin allergies) patterns. To determine the 
degree of a subject belonging to the identified patterns, i.e. adherence to a pattern, factor 
scores were calculated: low and high adherence for the first and third tertile, respectively. 
Logistic regressions were performed to evaluate the association of each MP and adherence 
tertiles with PDAC. Time since diagnosis of morbidities to PDAC diagnosis/recruitment was 
explored through stratification as recent (<3 years) and long-term (>3 years). Variables whose 
associations resulted in an OR change >1.5 after stratification by time since diagnosis were 
combined into a single variable for further analysis. Interaction between MPs and age, sex, and 
smoking were calculated comparing models with and without interaction terms through 
likelihood ratio test. Additive interactions of morbidities within each MP were also tested 
(Supplementary Methods). Excluding patients from Italy did not modify the results. 
Heterogeneity by country was not significant (p-value >0.2). Internal validation of these models 
was also performed (Supplementary Methods) 
Multimorbidity system analysis was performed with DisGeNET (Supplementary 
Methods). 
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Results 
Demographic and lifestyle information is provided in Supplementary Table S2.  
 
Individual conditions.  
Number of morbidities reported was similar among cases and controls (~7% zero morbidities; 
~38% >4 morbidities). When comparing subjects reporting zero morbidities with those reporting 
>4, the former were younger (mean age 59 vs. 67 years), less heavy smokers (15.5% vs. 
20.1%), and more commonly males (61.1% vs. 53.3%).  
 
Comorbidity assessment. 
Most morbidities (81%) associated with each other in the same direction in cases and controls, 
with only moderate differences (Supplementary Figure 1). Nine comorbidities and four 
trimorbidities were significantly associated with PDAC after multiple test correction 
(Supplementary Table S4). The strongest positive association was observed for “T2DM and 
acid regurgitation” (OR, 4.25; 95%CI, 2.55-7.08). The average SPP for these associations was 
93.3, i.e. if the analysis were repeated 100 times the association would be statistically 
significant 93 times after multiple test correction. Significant trimorbidities (average SPP, 93.4) 
always included T2DM and a combination of other conditions with ORs around 4, suggesting 
that the association of T2DM with PDAC risk might be potentiated by some morbidities. 
 
Multimorbidity assessment.  
Three clear patterns of conditions emerged: 1) Gastric:  heartburn, acid regurgitation, H. pylori, 
and ulcer; 2) MetS: obesity, T2DM, hypercholesterolemia and hypertension; and 3) Atopic: 
nasal allergies, skin allergies and asthma (Figure 1). The remaining conditions did not follow a 
consistent pattern of co-occurrence and were not considered in further analyses. 
A positive association was observed between PDAC risk and the gastric and MetS 
patterns with a positive trend (p-value <0.01); a negative association was observed in the atopic 
pattern (Table 1). Similar findings were observed when comparing the highest with the lowest 
adherence tertiles. An interaction was observed between MetS and sex; >3 MetS conditions 
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was associated with PDAC in males but not in females (p-value = 0.032, Supplementary Table 
S5).  
 
Time since diagnosis. 
Associations do not necessarily indicate causality; therefore, we assessed the 
associations  in relation to the period since diagnosis of conditions and PDAC.  Recent 
diagnosis of the gastric pattern showed stronger association with PDAC risk than long-term 
diagnosis (OR and 95%CI: 6.13, 3.01-12.5; 1.17, 0.79-1.73; respectively). Stratification of the 
MetS pattern was done based of T2DM diagnosis because the other conditions did not show 
different associations with PDAC by time since diagnosis: OR, 1.61; 95%CI, 1.11-2.35 for 
recent and OR, 1.35; 95%CI, 0.99-1.85 for long-term diagnosis. This analysis could not be 
performed for the atopic pattern because time since diagnosis was only available for asthma. 
 Gastric MP and T2DM showed the greatest change in their association with PDAC after 
stratification by time since diagnosis (Supplementary Table S3). Considered altogether, having 
>1 of these was strongly associated with PDAC among subjects with recent diagnosis (OR, 
7.89; 95%CI, 3.9-16.1 for >2 conditions) while a moderate estimate was observed among 
subjects with long-term diagnosis (OR, 1.86; 95%CI, 1.29-2.67 for >3 conditions, Table 2). The 
average AUC for this model was 0.78 (SD= 0.011) for recently diagnosed conditions; and 0.72 
(SD= 0.01) and 0.74 (SD= 0.009) for long-term and lifetime models, respectively (data not 
shown). Treating obesity as a confounder showed similar results (Supplementary Table S6).  
Bioinformatics analysis showed a stronger genetic link among morbidities included in 
the metabolic and atopic patterns in comparison to those of the gastric pattern, possibly due to 
less reported disease-gene associations in the latter. All patterns shared genetic links with 
PDAC (Supplementary Figure S2), and many of these conditions shared inflammatory related 
genes such as TNF, CXCL8, HIF1A, and PTGS2 (Supplementary Figure S3).  
 
Discussion 
We analyzed the aggregation and association of 17 self-reported medical conditions with PDAC 
risk in a large case-control European study. We identified three MPs: the gastric and MetS 
patterns, positively associated with PDAC, and the atopic pattern, negatively associated. 
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Moreover, we explored MPs in the temporal context of pancreatic cancer which provides clues 
about common mechanisms and causal effect. 
Among the gastric pattern, sensitivity analysis showed that heartburn and acid 
regurgitation had the strongest effect on the association. In the MetS pattern, T2DM was the 
main driving condition since removing T2DM from the pattern resulted in loss of significance. In 
the atopic pattern, none of the conditions seemed to drive the association individually.  
 Associations between gastric and MetS patterns with PDAC were significant only 
among subjects with recently diagnosed conditions. Our results strengthen previous findings 
with smaller case sample size or pooled heterogeneous populations reporting positive 
associations between history of gastric or duodenal ulcer with PDAC only among recently 
diagnosed subjects [2, 13, 14]. Two cohort studies reported a significant association between 
PDAC and long-term diagnosis (up to 20 years) of gastric but not duodenal ulcer [15, 16]; 
whether gastric ulcer was related to H. pylori infection was not elucidated. A recent meta-
analysis including ten case-control studies reported a non-significant association between 
overall H. pylori infection and PDAC [17]. These studies did not consider time since diagnosis 
and are limited in their ability to assess causality. Less information exists for acid regurgitation 
or heartburn. One study reported a significant positive association between PDAC and episodes 
of >4 weeks of heartburn up to 5 years prior to cancer diagnosis/interview [18]. For the MetS 
pattern, this observation was attributed to T2DM confirming and extending previous reports of a 
stronger positive association among new-onset diabetics [4, 19]. Importantly, the significant 
association between three or more MetS conditions and PDAC was restricted to males, pointing 
to a potential role of BMI since, contrary to females, there were more obese males among 
cases (22.6%) than controls (18.9%). Previous studies reported contradictory results on the 
interaction between MetS and sex [7, 8, 11, 12], more studies are needed to confirm our 
observations. Although recent asthma diagnosis was reported by <1%, long-term asthmatics 
were negatively associated with PDAC. Consistently, a significant inverse association between 
PDAC and nasal allergies unrelated to disease duration has been reported [20].  
 Five conditions (i.e. T2DM and gastric conditions) stood out by the magnitude of OR 
change after stratification by time since diagnosis. When consolidated into a single variable, a 
stronger positive association was observed between having >1 of these conditions recently 
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diagnosed and PDAC. T2DM was an important driver of this association, but having >3 of these 
conditions showed a stronger estimate than by T2DM alone highlighting the potential 
significance of combining morbidities when studying PDAC. Bootstrapped AUCs showed a fair 
performance of the models including these five conditions; restriction to recent diagnosis 
resulted in the best performance. Conceivably, additive interactions between morbidities within 
MPs could explain these results. In this regard we observed a significant additive interaction 
between asthma and both nasal and skin allergies, and a significant sub-additive interaction 
between diabetes and the combination of any three or more gastric conditions; however, we 
were limited by sample size in these analyses. Mechanistically, these associations might be 
explained in the context of systemic inflammation: early events during PDAC carcinogenesis 
could favor the development of type 3c diabetes, altogether prompting dysbiosis which could, in 
turn, be manifested as gastric conditions. Further analysis showed an intricate genetic system 
among the MPs and pancreatic cancer pointing to a potential mechanistic link between these 
(Supplementary Figure S2 and S3).  
It has been hypothesized that PDAC development might occur during the ten years 
previous to its detection with disease manifestations in the preceding 1-2 years. Yet, there are 
arguments in favor of a rapid "catastrophic" evolution shortly before diagnosis [21]. We aimed at 
discriminating medical conditions acting as true risk/protective factors (long-term diagnosis) vs. 
early manifestations of PDAC (recent diagnosis). We show that long-term T2DM and asthma 
are associated with PDAC, pointing to them as true risk and protective factors, respectively. 
Interestingly, the co-occurrence of long-term T2DM with long-term gastric conditions was 
associated with a stronger PDAC risk than that conferred by T2DM alone indicating that while 
T2DM is a main risk factor of PDAC, its overlap with other gastric conditions might further 
aggravate carcinogenesis. We also provide strong evidence that several conditions associate 
with PDAC risk only when diagnosed shortly before PDAC, suggesting that these could be 
PDAC manifestations. This concept has been discussed in the context of T2DM [4, 13, 19, 22, 
23], and it is further supported by studies showing improvement of insulin resistance and 
glucose intolerance after PDAC resection [24, 25]. However, we cannot rule out that 
pathophysiologically distinct subtypes of T2DM and/or other conditions might accelerate PDAC 
progression resulting in a shorter time between diagnoses.  
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Early PDAC diagnosis provides the only opportunity for long-term survival. Establishing 
a set of conditions alerting the clinical staff of potential PDAC cases could improve diagnosis, 
management and/or treatment of patients and consequently, the outcome of the disease. 
However, the symptoms/conditions here described are relatively non-specific hindering their 
immediate adscription to PDAC. Moreover, whether PDAC stage at diagnosis modifies the 
reported associations deserves further investigation.  While innovative and detailed analyses 
have been performed to both identify MPs and to assess their risk with PDAC, bias by 
unmeasured confounders is always a concern (i.e., metformin or statins medications have been 
associated with decreased risk of PDAC). Future studies should focus on exploring the role of 
particular treatments in these associations.  
Our study has some limitations. The information was self-reported thus, 
misclassification and bias cannot be completely ruled out; nevertheless, the consistency of 
basic findings in this report with existing literature argues against this possibility. Our study is 
one of the largest performed but - despite its size and the restriction of our analyses to 
conditions with a frequency >2% in cases and controls – statistical power remains an issue 
when considering multimorbidities and stratification by time since diagnosis. 
To our knowledge, this is the first study that simultaneously considers the association of 
many morbidities with PDAC. We report three main MPs significantly associated with PDAC and 
show that the associations change depending on the time since diagnosis of morbidities. Owing 
the high prevalence of multimorbidities, evaluating MPs may help to improve the 
characterization of PDAC risk. Confirmation of these results in independent studies will be 
critical in their generalization and future clinical application. Identification of early manifestations 
of PDAC may help define subpopulations of patients in whom screening might be cost-effective 
[26]. Moreover, the discovery of risk and protective associations should lead to more 
pathophysiological studies. Thus, the knowledge generated could contribute to implement novel 
preventive and therapeutic strategies.  
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Felipe Bory, Lucía Márquez Mosquera, Ignasi Poves Prim, Fernando Burdío, Luis Grande, Mar 
Iglesias, Javier Gimeno. 
Hospital Vall d´Hebron, Barcelona, Spain: Xavier Molero1, Luisa Guarner, Joaquin Balcells. 
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Figure Legends 
 
Figure 1. Clustering of morbidities in pancreatic ductal adenocarcinoma cases and 
controls. A) Dendrogram depicting Hierarchical cluster analysis using Yule’s Q distance matrix, 
B) Loadings from principal component analysis, C) Loadings from factor analysis. Loadings >0.3 
are considered to belong to the same component and factor, respectively. Yule’s Q distance 
was calculated as (1 - ((ad-bc)/(ad+bc))), where a indicates presence of both conditions, b and 
d absence of one condition and presence of the other, and d absence of both conditions. 
PanGenEU, 2009-2014. 
 
 
 
 
Table 1. Association between multimorbidity patterns and pancreatic ductal adenocarcinoma. 
Gastric pattern
a
 
Lifetime gastric conditions 
Number of conditions 
Cases Controls OR
 
(95% CI) 
p for trend
e
 
n=1705 % n=1084 % Unadjusted Adjusted
d
 
   0 987 57.9 709 65.4 1[Reference] 1[Reference]  
   1 319 18.7 182 16.8 1.26 (1.02-1.55) 1.34 (1.07 – 1.68)  
   2 292 17.1 135 12.5 1.55 (1.24-1.95) 1.65 (1.29 – 2.10)  
107 6.3 58 5.4 1.32 (0.95-1.85) 1.46 (1.01 – 2.10) <0.01 
High adherence
f 
615 36.1 315 29.1   1.22 (0.99 – 1.51)   
Recent gastric conditions 
n=1177 % n=725 %       
   0 987 83.9 709 97.8 1[Reference] 1[Reference]   
   1 111 9.4 7 1.0 11.4 (5.27-24.6) 12.3 (5.63 – 26.9)  
79 6.7 9 1.2 6.30 (3.14-12.7) 6.13 (3.01 – 12.5) <0.01 
High adherence
f
 432 36.7 203 28.0   2.17 (1.64 – 2.87)   
Long-term gastric conditions 
n=1479 % n=1059 %      
   0 987 66.7 709 66.9 1[Reference] 1[Reference]  
   1 211 14.3 176 16.6 0.86 (0.69-1.07) 0.89 (0.70 – 1.14)  
   2 202 13.7 121 11.4 1.19 (0.94-1.53) 1.29 (0.99 – 1.68)  
79 5.3 53 5.0 1.07 (0.75-1.54) 1.17 (0.79 – 1.73) 0.14 
High adherence
f
 491 33 355 33.5   0.79 (0.63 – 0.98)   
  
50
51
52
53
54
55
56
57
58
59
60
MetS pattern
b
 
Lifetime T2DM 
n=1705 % n=1084 %    
591 34.7 372 34.3 1[Reference] 1[Reference]  
526 30.9 349 32.2 0.94 (0.78-1.14) 1.10 (0.89 – 1.36)  
372 21.8 256 23.6 0.91 (0.74-1.12) 1.11 (0.88 – 1.39)  
216 12.7 107 9.9 1.27 (0.97-1.66) 1.62 (1.22 – 2.17) <0.01 
High adherence
f
 572 33.5 359 33.1   1.24 (1 – 1.53)  
Recent T2DM 
n=1458 % n=963 %      
591 40.5 372 38.6 1[Reference] 1[Reference]  
466 32.0 322 33.4 0.91 (0.75-1.10) 1.05 (0.85 – 1.30)  
289 19.8 213 22.1 0.85 (0.69-1.06) 1.05 (0.83 – 1.35)  
112 7.7 56 5.8 1.26 (0.89-1.78) 1.61 (1.11 – 2.35) 0.06 
High adherence
f
 498 34.2 314 32.6   1.37 (1.09 – 1.73)  
Long-term T2DM 
n=1523 % n=1060 %      
591 38.8 372 35.1 1[Reference] 1[Reference]  
492 32.3 346 32.6 0.89 (0.74-1.08) 1.03 (0.83 – 1.27)  
287 18.8 248 23.4 0.73 (0.59-0.90) 0.89 (0.70 – 1.13)  
153 10.0 94 8.9 1.02 (0.77-1.37) 1.35 (0.99 – 1.85) 0.25 
High adherence
f
 489 32.1 372 35.1   1 (0.80 – 1.25)  
  
50
51
52
53
54
55
56
57
58
59
60
Atopic pattern
c
 
Lifetime atopic conditions 
    n=1705 % n=1084 %       
1100 64.5 610 56.3 1[Reference] 1[Reference]  
485 28.4 353 32.6 0.76 (0.64-0.90) 0.77 (0.64 – 0.92)  
100 5.9 105 9.7 0.53 (0.39-0.71) 0.54 (0.39 – 0.74)  
20 1.2 16 1.5 0.69 (0.36-1.35) 0.66 (0.32 – 1.37) <0.01 
High adherence
f
 510 29.9 438 40.4  0.45 (0.36 – 0.55)   
 Gastric pattern: heartburn, acid regurgitation, H. pylori and ulcer. 
 MetS pattern: obesity, T2DM, hypercholesterolemia and hypertension. 
Atopic pattern: skin allergies, nasal allergies and asthma. Time since diagnosis was not available for nasal and skin allergies. 
Adjusted for age (continuous), sex, country, smoking (tertiles of pack/years), and number of morbidities excluding those  
tested in each model. 
value for trend was calculated using variables with 4 categories (0,1,2, >3) as continuous in the model. 
Tertiles of factor scores on the overall group of cases and controls. High adherence (tertile III) compared to low adherence (tertile I). 
Abbreviation: H. pylori, Helicobacter pylori; MetS, metabolic syndrome; T2DM, type 2 diabetes mellitus. 
50
51
52
53
54
55
56
57
58
59
60
Table 2. Association between the combination of T2DM and gastric conditions with pancreatic ductal adenocarcinoma. 
T2DM + Gastric conditions
a
  
Lifetime conditions 
Number of conditions 
Cases Controls OR (95% CI) 
p for 
trend
c
 
n=1705 % n=1084 %  Unadjusted  Adjusted
b
 
   0 730 42.8 610 56.3 1[Reference] 1[Reference]  
   1 482 28.3 256 23.6 1.57 (1.31-1.89) 1.76 (1.43 – 2.16)  
   2 322 18.9 150 13.8 1.79 (1.44-2.24) 1.98 (1.55 – 2.51)  
171 10.0 68 6.3 2.10 (1.56-2.84) 2.58 (1.87 – 3.57) <0.01 
Recent conditions 
n=1009 % n=640 %       
   0 730 72.3 610 95.3 1[Reference] 1[Reference]   
   1 193 19.1 21 3.3 7.68 (4.83-12.2) 7.80 (4.84 – 12.6)  
86 8.5 9 1.4 7.98 (3.98-15.9) 7.89 (3.9 – 16.1) <0.01 
Long-term conditions 
n=1318 % n=1037 %       
   0 730 55.4 610 58.8 1[Reference] 1[Reference]   
   1 292 22.2 235 22.7 1.04 (0.85-1.27) 1.18 (0.94 – 1.48)  
   2 190 14.4 134 12.9 1.18 (0.92-1.52) 1.29 (0.99 – 1.69)  
106 8.0 58 5.6 1.53 (1.09-2.14) 1.86 (1.29 – 2.67)  <0.01 
Heartburn, acid regurgitation, H. pylori, and ulcer. 
Adjusted for age (continuous), sex, country, smoking (tertiles of pack/years), and number of morbidities excluding those tested in each model.  
 value for trend was calculated using variables with 4 categories (0,1,2, >3) as continuous in the model. 
Abbreviation: H. pylori, Helicobacter pylori; T2DM, type 2 diabetes mellitus. 
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Clustering of morbidities in pancreatic ductal adenocarcinoma cases and controls. A) Dendrogram depicting 
Hierarchical cluster analysis using Yule’s Q distance matrix, B) Loadings from principal component analysis, 
C) Loadings from factor analysis. Loadings >0.3 are considered to belong to the same component and 
factor, respectively. Yule’s Q distance was calculated as (1 - ((ad-bc)/(ad+bc))), where a indicates presence 
of both conditions, b and d absence of one condition and presence of the other, and d absence of both 
conditions. PanGenEU, 2009-2014.  
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Supplementary Methods 
Imputation 
Imputation of missing values (2.4% in cases and 2.6% in controls) was performed with missForest R 
package. Variables for imputation (% missings) included case-control status, country, age (2.3%), sex 
(0.2%), smoking (pack/years, 9.4%), and morbidities and time since their diagnosis (0.8%-21.7%). 
Imputation was performed without maximum number of iteration and 100 trees. Random attribution of 
missing values to the complete dataset mimicking the missing proportions in the original dataset 
resulted in an averaged correct assignment of 93.7% after imputation. Out of bag (OOB) error for 
imputation was <0.31, mean: 0.04, SD=0.09 (0= good performance, 1= bad performance). 
Frequencies between imputed and complete-data were not significantly different (p value >0.38). 
Comorbidity and trimorbidity models 
All combinations of two and three medical conditions within an individual were considered: 136 
comorbidities and 680 trimorbidities (62 excluded due to cells with zero counts). Odds ratios (ORs) for 
each comorbidity and trimorbidity were calculated and visualized by a heatmap using plotrix package 
[Lemon 2006]. p values for co and trimorbidity analyses were adjusted for multiple testing with 
Bonferroni’s method where a Bonferroni corrected p-value of 0.05 equals a p-value before correction 
of 3x10-3 in comorbidities and a p-value of 8x10-5 in trimorbidities [Bland 1995].. Robustness was 
assessed with bootstrapped samples (n=1,000) drawn with replacement from the original dataset 
preserving the sample size. The selection probability proportion (SPP) was calculated as the 
proportion of models that remained significant for each variable after multiple test correction ((number 
of significant models*100)/1000)  [Pineda 2014]. 
Multimorbidity patterns 
Multimorbidity patterns (MPs) were defined separately for cases and controls using hierarchical cluster 
analysis, principal component (PCA), and factor (FA) analyses. Hierarchical agglomerative cluster 
analysis was conducted with stats and proxy R packages using the average linkage method and 
Yule’s Q distance (1-((ad-bc)/(ad+bc))) matrix for all possible combinations of the 17 morbidities. PCA 
and exploratory FA with a principal factor solution were carried out using a tetrachoric correlation 
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matrix. Scree plots and eigenvalues greater than 1 from both cases and controls were used to 
determine the number of components. An orthogonal (varimax) rotation of the loading matrix was 
applied to obtain a simpler structure and improve interpretability while providing uncorrelated factors. 
The magnitude of each loading indicates the relevance of the correspoinding medical condition to the 
component/factor. MPs were determined according to those conditions with loadings >0.30 in their 
respective components and factors [Laher 2010]. The same number of components/factors (n=3) was 
retained for cases and controls and the three methods. Moreover, the biological rationale of the MPs 
was considered for their selection.  
As internal validation, estimates were calculated using new samples generated by 
bootstrapping with replacement (n=10,000) while preserving the original sample size. Receiver 
operating characteristic (ROC) curves and the corresponding area under the curve (AUC) were 
calculated for the new samples generated with pROC R package. Mean and standard deviation (SD) 
were calculated for the resulting AUCs. 
Multimorbidity system analysis 
DisGeNET version 3.0, a bioinformatics-tool that correlates human diseases and their associated 
genes from information available in UniProt, CTD, ClinVar databases [Piñero 2015], was used to 
obtain information about genes associated with the MPs and PDAC. The Jaccard index (JI) was 
calculated to assess disease similarity based in common genes while accounting for variation in gene 
findings, i.e. diseases with larger versus smaller number of genes. The JI is defined as: |Genesdis1 ∩ 
Genesdis2| / |Genesdis1 U Genesdis2|, where Genesdis1 and Genesdis2 are the genes associated with 
disease 1 and 2, respectively, ∩ is the intersection operator, and U is the union operator between the 
two sets of genes. The disease system figure was created using the DisGeNET plugin for Cytoscape 
2.8.3. 
Additive interactions for multimorbidity patterns 
The additive interaction between morbidities within multimorbidity patterns was evaluated using the 
Relative Excess Risk due to Interaction (RERI) with the EpiR package in R. Variables were created 
that included all or none of three morbidities of a pattern (or two en the case of the atopic pattern) and 
compared with the presence (yes) or absence (no) of the fourth (or third) morbidity of a pattern; all 
 3 
Gomez-Rubio et al. Multimorbidities and pancreatic cancer 
possible combinations were tested. For the pattern of diabetes and gastric comorbidities the additive 
interaction was tested between each morbidity and the combination of any three or more morbidities 
(we were unable to test the full model due to low sample size). 
References 
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Supplementary Figure Legends 
Supplementary Figure S1. Heatmap of the associations between comorbidities in pancreatic ductal 
adenocarcinoma cases and controls. White cells represent an OR=1, shades of blue represent ORs 
below 1, and shades of red represent ORs above 1. ORs are presented for the association between 
the condition in the left and the condition in the bottom of each square. All models were adjusted for 
age, sex, country, smoking (pack/years) and number of morbidities. The asterisks represent statistical 
significance after Bonferroni´s correction. PanGenEU, 2009-2014. 
Supplementary Figure S2. Genetic system for multimorbidity patterns and pancreatic cancer. 
Association between pancreatic cancer and medical conditions of the detected multimorbidity 
patterns based on the number of shared genes. Edge width represents the Jaccard index for each 
disease pair; Jaccard indexes were multiplied by 100 for better visualization. Node size represents 
the number of genes obtained through DisGeNET for each medical condition. 
Supplementary Figure S3. Venn diagrams showing the number of shared genes between each 
multimorbidity pattern and pancreatic cancer. A) Overlapping genes for atopic pattern conditions 
and pancreatic cancer; B) Overlapping genes for gastric pattern conditions and pancreatic cancer; C) 
Overlapping genes for metabolic syndrome pattern conditions and pancreatic cancer. The squares 
show the genes shared between different medical conditions and pancreatic cancer.  
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Supplementary Table S1. Diagnosed conditions at admission for hospital controls. PanGenEU, 2009-
2014. 
Disease Group Conditions 
Diseases of the circulatory 
system 
Hemorrhoids 
 
Diseases of the digestive 
system 
Appendicitis, appendiceal abscess, inguinal hernia and other 
abdominal hernias, fissure and fistula of anal and rectal 
regions, anal prolapse, rectal prolapse, stenosis of anus and 
rectum 
 
Diseases of the skin and 
subcutaneous tissue 
Cutaneous abscess, furuncle, cellulitis, pilonidal cyst 
Diseases of the genitourinary 
system 
Varicocele, spermatocele, congenital spermatocele, 
hydrocele and spermatocele, torsion of testis. 
Exclude: congenital hydrocele  
 
Injury, poisoning and other 
consequences of external 
causes 
Fractures including prosthesis due to fractures, dislocations, 
sprains, internal injuries of thorax, abdomen and pelvis. Open 
wounds of the superior and inferior extremities. Other 
diseases of external causes, burns, plastic surgery (due to 
burns, accidents) 
 
Diseases of the 
musculoskeletal system and 
connective tissue 
Acquired deformities of toe (exclude congenital deformations), 
change of orthopedic prosthesis due infection, sacral cyst 
Diseases of the eye and 
adnexa and diseases of the 
ear and mastoid process 
Cornea transplant, retinal detachments and breaks, 
cholesteatoma (cleaning of), tympanoplasty due perforation of 
tympanic membrane.  
Operations on the nose, 
mouth, and pharynx 
Nasal septoplasty, turbinectomy, uvulopalatoplasty 
Diseases of the respiratory 
system 
Spontaneous pneumothorax 
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Supplementary Table S2.  Distribution of cases and controls according to selected variables. 
PanGenEU, 2009-2014. 
Cases  Controls 
n=1705 %  n=1084 % 
Country   
 
  
Spain 842 49.4  595 54.9 
England 121 7.1  22 2.0 
Germany 140 8.2  110 10.1 
Ireland 173 10.1  290 26.8 
Italy 292 17.1  0  
Sweden 137 8.0  67 6.2 
Sex   
 
  
Female 741 43.5  518 47.8 
Male 964 56.5  566 52.2 
Age   
 
  
    < 54 363 21.3  221 20.4 
    55 - 64 413 24.2  230 21.2 
    65 - 74 592 34.7  333 30.7 
    > 75 337 19.8  300 27.7 
Smoking (pack/years)   
 
  
Never 673 39.5  540 49.8 
< 18.5 315 18.5  233 21.5 
18.6 - 40.9 365 21.4  145 13.4 
    > 41  352 20.6  166 15.3 
Number of  morbidities   
 
  
    0 117 6.9  76 7.0 
    1 267 15.7  171 15.8 
    2 348 20.4  215 19.8 
    3 328 19.2  207 19.1 
    4 292 17.1  194 17.9 
    5 177 10.4  117 10.8 
    >6 176 10.3  104 9.6 
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Supplemetary Table S3. Frequency of medical conditions in cases and controls, and corresponding 
odds rations and 95% condifence intervals. PanGenEU, 2009-2014. 
Cases Controls OR
a 
(95%CI) 
  n=1705 % n=1084 % 
Rheumatoid arthritis      
   No 1597 93.7 1000 92.3 1 [Reference] 
   Yes 108 6.3 84 7.7 0.75 (0.54-1.03) 
Pernicious anemia      
   No 1630 95.6 1014 93.5 1 [Reference] 
   Yes 75 4.4 70 6.5 0.72 (0.50-1.02) 
Hyperthyroidism      
   No 1648 96.7 1041 96.0 1 [Reference] 
   Yes 57 3.3 43 4.0 0.83 (0.54-1.28) 
Hypothyroidism      
   No 1612 94.5 1023 94.4 1 [Reference] 
   Yes 93 5.5 61 5.6 1.07 (0.74-1.54) 
Mumps      
   No 1023 60.0 616 56.8 1 [Reference] 
   Yes 682 40.0 468 43.2 0. 83 (0.69-0.99) 
Cancer      
   No 1502 88.1 953 87.9 1 [Reference] 
   Yes 203 11.9 131 12.1 1.03 (0.80-1.33) 
Diabetes      
   No 1276 74.8 939 86.6 1 [Reference] 
   Yes 429 25.2 145 13.4 2.25 (1.79 - 2.81) 
   <3y 182 10.7 24 2.2 5.27 (3.38 - 8.23) 
   >3y 247 14.5 121 11.2 1.61 (1.25 - 2.07) 
Hypertension      
   No 1070 62.8 659 60.8 1 [Reference] 
   Yes 635 37.2 425 39.2 0.94 (0.79 - 1.12) 
   <3y 90 5.3 50 4.6 0.96 (0.65 - 1.42) 
   >3y 545 32.0 375 34.6 0.93 (0.78 - 1.12) 
Hypercholesterolemia     
   No 1167 68.4 691 63.7 1 [Reference] 
   Yes 538 31.6 393 36.3 1.05 (0.88 - 1.25) 
   <3y 106 6.2 69 6.4 1.25 (0.89 - 1.75) 
   >3y 432 25.3 324 29.9 1 (0.83 - 1.21) 
Obesity
b
      
   No 1350 79.2 855 78.9 1 [Reference] 
   Yes 355 20.8 229 21.1 1.05 (0.86 - 1.29) 
Helicobacter pylori      
   No 1556 91.3 1016 93.7 1  [Reference] 
   Yes 149 8.7 67 6.3 1.31 (0.94-1.82) 
   <3y 42 2.5 6 0.6 3.64 (1.49 - 8.94) 
   >3y 107 6.3 61 5.6 1.08 (0.75 - 1.56) 
Acid Regurgitation      
   No 1293 75.8 888 81.9 1 [Reference] 
   Yes 412 24.2 196 18.1 1.59 (1.29 - 1.96) 
   <3y 126 7.4 18 1.7 5.02 (2.99 - 8.42) 
   >3y 286 16.8 178 16.4 1.22 (0.97 - 1.53) 
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Supplementary Table S3. Frequency of medical conditions in cases and controls and corresponding 
odds ratios, and 95% confidence intervals. PanGenEU, 2009-2014. (continued) 
Cases Controls OR
a 
(95%CI) 
  n=1705 % n=1084 % 
Heartburn      
   No 1217 71.4 829 76.5 1 [Reference] 
   Yes 488 28.6 255 23.5 1.42(1.17 – 1.73) 
   <3y 130 7.6 11 1.0 8.23 (4.36 – 15.3) 
   >3y 358 21.0 244 22.5 1.09 (0.88 – 1.34) 
Ulcer      
   No 1516 88.9 966 89.1 1 [Reference] 
   Yes 186 11.1 118 10.9 1.03 (0.78 – 1.34)  
   <3y 24 1.4 4 0.4 2.89 (0.97 – 8.61) 
   >3y 162 9.5 114 10.5 0.91 (0.69 – 1.20) 
Asthma      
   No 1580 92.7 969 89.4 1 [Reference] 
   Yes 125 7.3 115 10.6 0.61 (0.45 – 0.82) 
   <3y 8 0.5 4 0.4 1.75 (0.49 – 6.2) 
   >3y 117 6.9 111 10.2 0.58 (0.42 – 0.78) 
Nasal allergies
c
      
   No 1465 85.9 865 79.8 1 [Reference] 
   Yes 240 14.1 219 20.2 0.66 (0.53 – 0.83) 
Skin allergies
c
      
   No 1325 77.7 807 74.4 1[Reference] 
   Yes 380 22.3 277 25.6 0.84 (0.68 – 1.03) 
Chronic pancreatitis      
   No 1689 99.1 1083 99.9 1 [Reference] 
   Yes 16 0.9 1 0.1 6.01 (0.74 – 4.85) 
Lupus      
   No 1696 99.5 1081 99.7 1 [Reference] 
   Yes 9 0.5 3 0.3 1.88 (0.47-7.51) 
Scleroderma      
   No 1697 99.5 1080 99.6 1 [Reference] 
   Yes 8 0.5 4 0.4 0.79 (0.2 – 3.12) 
Polymyalgia      
   No 1692 99.2 1065 98.2 1 [Reference] 
   Yes 13 0.8 19 1.8 0.38 (0.17-0.85) 
Crohn’s disease      
   No 1701 99.8 1079 99.5 1 [Reference] 
   Yes 4 0.2 5 0.5 0.27 (0.46-1.62) 
Ulcerative colitis      
   No 1690 99.1 1068 98.5 1 [Reference] 
   Yes 15 0.9 16 1.5 0.48 (0.20-1.15) 
Celiac disease      
   No 1698 99.6 1078 99.4 1 [Reference] 
   Yes 7 0.4 6 0.6 0.59 (0.17-2.11) 
Addison's disease      
   No 1698 99.6 1078 99.4 1 [Reference] 
   Yes 7 0.4 6 0.6 0.87 (0.28-2.68) 
Adjusted for age, sex, country, smoking (pack/years), and number of morbidities.  
Calculated using weight at two years before recruitment. 
Information on time of diagnosis of the disease was not collected. 
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Supplemetary Table S4. Co and trumorbidities significantly associated with pancreatic ductal  
Adenocarcinoma after multiple test correction. PanGenEU, 2009-2014 
Cases/Controls
a
 OR
b 
(95%CI) Corrected 
p-value
c
 SPP 
Comorbidities     
Diabetes-Acid Regurgitation 91/23 4.25 (2.55-7.08) <0.01 99.9 
Diabetes-Heartburn 113/31 3.94 (2.49- 6.2) <0.01 100 
Diabetes-Obesity 131/39 2.39 (2.49-6.21) <0.01 95.9 
Diabetes-Hypercholesterolemia 184/65 2.36 (1.69-3.32) <0.01 99.4 
Diabetes-Hypertension 226/85 1.9 (1.38-2.59) 0.01 94.3 
Heartburn-Acid Regurgitation 317/152 1.62 (1.24-2.10) 0.04 84.1 
Nasal allergies-Hypertension 79/86 0.48 (0.32-0.70) 0.02 88.5 
Nasal allergies- Skin allergies 75/78 0.47 (0.32-0.69) 0.02 91.0 
Skin allergies-Pernicious anemia 19/31 0.32 (0.17-0.59) 0.04 87.0 
Trimorbidities     
Diabetes-Hypercholesterolemia-Acid regurgitation 41/11 4.81 (2.28-10.12) 0.02 90.7 
Diabetes-Hypercholesterolemia- Heartburn 48/14 4.54 (2.31-8.96) <0.01 94.0 
Diabetes-Heartburn-Acid regurgitation 62/17 4.40 (2.39-8.08) <0.01 96.7 
Diabetes-Hypertension-Acid regurgitation 52/14 4.29 (2.18-8.43) 0.01 92.2 
Subjects that report having all medical conditions 
Adjusted for age, sex, country, smoking (pack/years), and number of morbidities. Reference category: none of the two or three 
 medical conditions 
Bonferroni corrected p-value. A Bonferroni corrected p-value of  0.05 equals a p-value before correction of 3x10-3 in comorbidities and of 8x10-5 in trimorbidities. 
SPP: selection probability proportion 
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Supplementary Table S5. Association between metabolic syndrome pattern and pancreatic ductal adenocarcinoma stratified by sex. PanGenEU, 2009-2014. 
                                         Females Males 
 Cases Controls 
OR
a 
(95%CI) 
Cases Controls 
OR
a 
(95%CI)  Number of conditions  n=741 % n=518 % n=964 % n=566 % 
MetS pattern            
   0 267 36.0 162 31.3 1 [Reference] 324 33.6 210 37.1 1 [Reference] 
   1 237 32.0 162 31.3 1.09 (0.79-1.51) 289 30.0 187 33.0 1.08 (0.82-1.43) 
   2 155 20.9 139 26.8 0.92 (0.65-1.29) 217 22.5 117 20.7 1.31 (0.96-1.78) 
82 11.1 55 10.6 1.27 (0.83-1.98) 134 13.9 52 9.2 1.93 (1.31-2.85) 
MetS: Metabolic Syndrome (i.e. type 2 diabetes, hypertension, hypercholesterolemia, and obesity)
 
Adjusted for age, country, smoking (pack/years), and number of morbidities  
 value of interaction between MetS and sex:   0.032 
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Supplementary Table S6. Association between lifetime multimorbidity patterns and pancreatic ductal adenocarcinoma further adjusting for obesity. 
PanGenEU, 2009-2014. 
Cases   Controls        
 Number of conditions n=1705 % n=1084 %  OR* 95%CI 
 Gastric pattern 
987 57.9 709 65.4  1 Ref 
319 18.7 182 16.8  1.35 1.08-1.69 
292 17.1 135 12.5  1.65 1.29-2.10 
107 6.3 58 5.4  1.47 1.02-2.11 
 MetS pattern (excluding obesity) 
684 40.1 428 39.5  1 Ref 
549 32.2 391 36.1  0.98 0.81-1.19 
363 21.3 223 20.6  1.27 1.01-1.59 
109 6.4 42 3.9  1.97 1.97-2.94 
 Atopic pattern 
1100 64.5 610 56.3  1 Ref 
485 28.4 353 32.6  0.77 0.64-0.92 
100 5.9 105 9.7  0.54 0.39-0.75 
20 1.2 16 1.5  0.66 0.32-1.36 
 T2DM + Gastric conditions 
730 42.8 610 56.3  1 Ref 
482 28.3 256 23.6  1.76 1.43-2.16 
322 18.9 150 13.8  1.98 1.56-2.52 
171 10 68 6.3  2.59 1.87-3.59 
* Adjusted for age (continuous), sex, country, smoking (tertiles of pack/years), obesity (BMI <30 kg/m
2 
/ BMI >30 kg/m
2
) and number of morbidities excluding those tested and adjusted in each model. 
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